Pulse Biosciences to Report Second Quarter 2019 Operational Highlights and Financial Results
July 25 2019 - 4:20PM
Business Wire
Pulse Biosciences, Inc. (Nasdaq: PLSE) (“Pulse Biosciences” or
the “Company”), a novel bioelectric medicine company bringing to
market its proprietary CellFX™ System announced today that the
Company will report second quarter 2019 operational highlights and
financial results on Thursday, August 8, 2019. Pulse Biosciences
management will host a conference call at 4:30 p.m. Eastern Time
(ET) / 1:30 p.m. Pacific Time (PT).
Analysts and investors can participate in the conference call by
dialing (844) 494-0190 (domestic) and (508) 637-5580
(international) using the conference ID# 9229379. The conference
call can also be accessed live on the Investor Relations section of
the Pulse Biosciences website at www.PulseBiosciences.com.
About Pulse Biosciences
Pulse Biosciences is a novel bioelectric medicine company
committed to health innovation that improves and extends the lives
of patients. The Company utilizes its patented groundbreaking
Nano-Pulse Stimulation™ (NPS™) technology to treat a variety of
applications for which an optimal solution remains unfulfilled. NPS
is a proprietary technology that delivers nano-second pulses of
high amplitude electrical energy to non-thermally clear targeted
cells while sparing adjacent non-cellular tissue. The cell-specific
effects of NPS technology have been validated in a series of
ongoing clinical trials. In addition, early pre-clinical evidence
suggests that NPS technology holds a promising future in
immuno-oncology by demonstrating an ability to induce immunogenic
cell death. The CellFX System, the first planned commercial product
to harness the distinctive advantages of NPS technology, is
preparing to launch in 2019 as a multi-application platform
designed to address a broad range of dermatologic conditions. As
part of the customer experience, the Company is offering a
utilization-based revenue model and easy-access customer portal
offering a suite of services. CellFX procedures offer customer
value across an expanding spectrum of clinical applications. The
initial commercial use will be in the clearance of common skin
lesions, including sebaceous hyperplasia (SH) and seborrheic
keratosis (SK) – two prevalent and difficult-to-treat benign skin
conditions that share high demand among patients and practitioners
for improved and durable aesthetic outcomes that lead to greater
overall satisfaction. For more information about Pulse Biosciences,
proprietary NPS technology, or the CellFX System, please visit us
at PulseBiosciences.com.
Caution: Pulse Biosciences’ CellFX System and Nano-Pulse
Stimulation (NPS) technology are for investigational use only.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190725005690/en/
Investor Relations: Pulse Biosciences, Inc. Brian Dow Sr.
Vice President and Chief Financial Officer IR@PulseBiosciences.com
Solebury Trout Gitanjali Jain Ogawa, 646-378-2949
gogawa@troutgroup.com Media: Tosk Communications Nadine D.
Tosk, 504-453-8344 nadinepr@gmail.com
Pulse Biosciences (NASDAQ:PLSE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Pulse Biosciences (NASDAQ:PLSE)
Historical Stock Chart
From Apr 2023 to Apr 2024